Bristol Myers Squibb is axing another big bet from the Caforio era, terminating a deal for Agenus’ TIGIT bispecific antibody three years after paying $200 million to buy into the program. Agenus ...

This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. A few years back, TIGIT was hailed as the ...

Companies are searching high and low for ways to make checkpoint inhibitors work for more people. One solution Merck is trying out is combining different checkpoint blockers—and early data from its ...

Dublin, Dec. 21, 2021 (GLOBE NEWSWIRE) -- The "Global TIGIT Inhibitor Drug Opportunity & Clinical Research Insight 2022" report has been added to ResearchAndMarkets.com's offering. T-cell ...

The combination of Merck & Co’s PD-1 inhibitor Keytruda with experimental TIGIT inhibitor vibostolimab has generated disappointing results in a mid-stage lung cancer trial. The open-label KeyVibe-002 ...

The role of TIGIT as a target for immuno-oncology therapies has been called into question again after it was revealed that Novartis handed back rights to a drug partnered with China’s BeiGene. The ...

TIGIT inhibitors present a strong market opportunity, with numerous global players advancing in immuno-oncology. Key opportunities lie in developing and commercializing emerging therapies, especially ...

Researchers at the University of Sharjah are exploring a promising approach that could enhance the immune system's ability to fight cancer, potentially paving the way for new treatments. Subscribe to ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. This is the online edition of ESMO in 30 Seconds, a pop-up newsletter ...

GlaxoSmithKline has agreed to buy an anti-TIGIT antibody for cancer immunotherapy from iTeos Therapeutics for $625 million upfront and up to $1.45 billion in milestone payments. It’s the latest ...

Here we have identified a surface protein, TIGIT, containing an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif that was expressed on ...